SEATTLE--(BUSINESS WIRE)--Blaze Bioscience, Inc., a biotechnology company focused on guided cancer therapy, announced today that the company has been awarded a $1.5 million Small Business Innovation Research (SBIR) Phase II contract from the National Cancer Institute (NCI) to study Tumor Paint BLZ-100 in patients with soft tissue sarcoma1. The company received this award after the successful completion of the Phase I contract, which studied BLZ-100 in canine patients with multiple tumor types. The award will fund the Phase 1b study in human patients with soft tissue sarcoma undergoing tumor resection. The company recently announced the initiation of their Phase 1b program in brain cancer.
Help employers find you! Check out all the jobs and post your resume.
